1
|
Cardoso VMDO, Moreira BJ, Comparetti EJ, Sampaio I, Ferreira LMB, Lins PMP, Zucolotto V. Is Nanotechnology Helping in the Fight Against COVID-19? FRONTIERS IN NANOTECHNOLOGY 2020. [DOI: 10.3389/fnano.2020.588915] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
|
2
|
Weers JG, Miller DP. Formulation Design of Dry Powders for Inhalation. J Pharm Sci 2015; 104:3259-88. [DOI: 10.1002/jps.24574] [Citation(s) in RCA: 85] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2015] [Revised: 06/11/2015] [Accepted: 06/12/2015] [Indexed: 11/09/2022]
|
3
|
ElMeshad AN, Mortazavi SM, Mozafari MR. Formulation and characterization of nanoliposomal 5-fluorouracil for cancer nanotherapy. J Liposome Res 2013; 24:1-9. [DOI: 10.3109/08982104.2013.810644] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
4
|
Bandi N, Ayalasomayajula SP, Dhanda DS, Iwakawa J, Cheng PW, Kompella UB. Intratracheal budesonide-poly (lactide-co-glycolide) microparticles reduce oxidative stress, VEGF expression, and vascular leakage in a benzo(a)pyrene-fed mouse model. J Pharm Pharmacol 2010; 57:851-60. [PMID: 15969944 DOI: 10.1211/0022357056334] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Abstract
The purpose of this study was to determine whether intratracheally instilled polymeric budesonide microparticles could sustain lung budesonide levels for one week and inhibit early biochemical changes associated with benzo(a)pyrene (B[a]P) feeding in a mouse model for lung tumours. Polymeric microparticles of budesonide-poly (dl-lactide-co-glycolide) (PLGA 50:50) were prepared using a solvent evaporation technique and characterized for their size, morphology, encapsulation efficiency, and in-vitro release. The microparticles were administered intratracheally (i.t.) to B[a]P-fed A/J mice. At the end of one week drug levels in the lung tissue and bronchoalveolar lavage (BAL) were estimated using HPLC and compared with systemic (intramuscular) administration. In addition, in-vivo end points including malondialdehyde (MDA), glutathione (GSH), total protein levels and vascular endothelial growth factor (VEGF) in BAL, and VEGF and c-myc mRNA levels in the lung tissue were assessed at the end of one week following intratracheal administration of budesonide microparticles. Budesonide-PLGA microparticles (1–2 μm), with a budesonide loading efficiency of 69–94%, sustained in-vitro budesonide release for over 21 days. Compared with the intramuscular route, intratracheally administered budesonide-PLGA microparticles resulted in higher budesonide levels in the BAL and lung tissue. In-vivo, B[a]P-feeding increased BAL MDA, lung VEGF mRNA, lung c-myc mRNA, BAL total protein, and BAL VEGF levels by 60, 112, 71, 154, and 78%, respectively, and decreased BAL GSH by 62%. Interestingly, intratracheally administered budesonide-PLGA particles inhibited these biochemical changes. Thus, biodegradable budesonide microparticles sustained budesonide release and reduced MDA accumulation, GSH depletion, vascular leakage, and VEGF and c-myc expression in B[a]P-fed mice, indicating the potential of locally delivered sustained-release particles for inhibiting angiogenic factors in lung cancer.
Collapse
Affiliation(s)
- Nagesh Bandi
- Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198-6025, USA
| | | | | | | | | | | |
Collapse
|
5
|
Beck-Broichsitter M, Gauss J, Gessler T, Seeger W, Kissel T, Schmehl T. Pulmonary Targeting with Biodegradable Salbutamol-Loaded Nanoparticles. J Aerosol Med Pulm Drug Deliv 2010; 23:47-57. [DOI: 10.1089/jamp.2009.0759] [Citation(s) in RCA: 52] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Moritz Beck-Broichsitter
- Medical Clinic II, Department of Internal Medicine, Justus-Liebig-University Giessen, Klinikstrasse 36, D-35392 Giessen, Germany
- Department of Pharmaceutics and Biopharmacy, Philipps-University, Marburg, Ketzerbach 63, D-35037 Marburg, Germany
| | - Julia Gauss
- Medical Clinic II, Department of Internal Medicine, Justus-Liebig-University Giessen, Klinikstrasse 36, D-35392 Giessen, Germany
| | - Tobias Gessler
- Medical Clinic II, Department of Internal Medicine, Justus-Liebig-University Giessen, Klinikstrasse 36, D-35392 Giessen, Germany
| | - Werner Seeger
- Medical Clinic II, Department of Internal Medicine, Justus-Liebig-University Giessen, Klinikstrasse 36, D-35392 Giessen, Germany
| | - Thomas Kissel
- Department of Pharmaceutics and Biopharmacy, Philipps-University, Marburg, Ketzerbach 63, D-35037 Marburg, Germany
| | - Thomas Schmehl
- Medical Clinic II, Department of Internal Medicine, Justus-Liebig-University Giessen, Klinikstrasse 36, D-35392 Giessen, Germany
| |
Collapse
|
6
|
Literature Alerts. J Microencapsul 2008. [DOI: 10.3109/02652049309015327] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
7
|
Surti N, Misra A. Wheat germ agglutinin-conjugated nanoparticles for sustained cellular and lung delivery of budesonide. Drug Deliv 2008; 15:81-6. [PMID: 18293193 DOI: 10.1080/10717540801904846] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
Abstract
The purpose of our studies was to assess in vitro nanoparticles cellular uptake and cellular budesonide levels after treatment of alveolar epithelial cell lines with wheat germ agglutinin (WGA)-conjugated budesonide nanoparticles and pharmacokinetic evaluation of drug after intratracheal instillation of nanoparticles in rats. Confocal microscopy was used to study the cellular uptake of nanoparticles, and the cellular and lung tissue drug levels were estimated by HPLC. Higher amount of fluorescence observed in the cells treated with WGA nanoparticles, higher and sustained cellular drug levels, and better bioavailability in lungs of WGA-conjugated nanoparticles indicate superiority of WGA-conjugated nanoparticles over unconjugated nanoparticles.
Collapse
Affiliation(s)
- Naazneen Surti
- Pharmacy Department, Faculty of Technology and Engineering, Kalabhavan, The Maharaja Sayajirao University of Baroda, Gujarat, India
| | | |
Collapse
|
8
|
Xie Y, Zeng P, Wiedmann TS. Disease guided optimization of the respiratory delivery of microparticulate formulations. Expert Opin Drug Deliv 2008; 5:269-89. [PMID: 18318650 DOI: 10.1517/17425247.5.3.269] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
BACKGROUND Inhalation of microparticulate dosage forms can be effectively used in the treatment of respiratory and systemic diseases. OBJECTIVE Disease states investigated for treatment by inhalation of microparticles were reviewed along with the drugs' pharmacological, pharmacokinetic and physical chemical properties to identify the advantages of microparticulate inhalation formulations and to identify areas for further improvement. METHODS Microbial infections of the lung, asthma, diabetes, lung transplantation and lung cancer were examined, with a focus on those systems intended to provide a sustained release. CONCLUSION In developing microparticulate formulations for inhalation in the lung, there is a need to understand the pharmacology of the drug as the key to revealing the optimal concentration time profile, the disease state, and the pharmacokinetic properties of the pure drug as determined by IV administration and inhalation. Finally, in vitro release studies will allow better identification of the best dosing strategy to be used in efficacy and safety studies.
Collapse
Affiliation(s)
- Yuanyuan Xie
- University of Minnesota, Department of Pharmaceutics, 308 Harvard St SE, Minneapolis, MN 55455, USA
| | | | | |
Collapse
|
9
|
Chow AHL, Tong HHY, Chattopadhyay P, Shekunov BY. Particle Engineering for Pulmonary Drug Delivery. Pharm Res 2007; 24:411-37. [PMID: 17245651 DOI: 10.1007/s11095-006-9174-3] [Citation(s) in RCA: 417] [Impact Index Per Article: 24.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2006] [Accepted: 10/05/2006] [Indexed: 10/23/2022]
Abstract
With the rapidly growing popularity and sophistication of inhalation therapy, there is an increasing demand for tailor-made inhalable drug particles capable of affording the most efficient delivery to the lungs and the most optimal therapeutic outcomes. To cope with this formulation demand, a wide variety of novel particle technologies have emerged over the past decade. The present review is intended to provide a critical account of the current goals and technologies of particle engineering for the development of pulmonary drug delivery systems. These technologies cover traditional micronization and powder blending, controlled solvent crystallization, spray drying, spray freeze drying, particle formation from liquid dispersion systems, supercritical fluid processing and particle coating. The merits and limitations of these technologies are discussed with reference to their applications to specific drug and/or excipient materials. The regulatory requirements applicable to particulate inhalation products are also reviewed briefly.
Collapse
Affiliation(s)
- Albert H L Chow
- School of Pharmacy, The Chinese University of Hong Kong, Shatin, N.T., Hong Kong, SAR, China.
| | | | | | | |
Collapse
|
10
|
Jaspart S, Bertholet P, Piel G, Dogné JM, Delattre L, Evrard B. Solid lipid microparticles as a sustained release system for pulmonary drug delivery. Eur J Pharm Biopharm 2007; 65:47-56. [PMID: 16962749 DOI: 10.1016/j.ejpb.2006.07.006] [Citation(s) in RCA: 72] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2006] [Revised: 07/03/2006] [Accepted: 07/12/2006] [Indexed: 10/24/2022]
Abstract
The controlled release of drugs for pulmonary delivery is a research field which has been so far rather unexploited but is currently becoming increasingly attractive. The introduction part of this research article first details the potential advantages of solid lipid microparticles (SLMs) as drug carrier compared to liposomes and polymeric microspheres. The aim of this work is to use SLMs to impart a sustained release profile to a model drug, salbutamol acetonide (SA). SA was synthesized from salbutamol in order to increase the lipophilicity of this molecule and thereby to increase its incorporation efficiency into SLMs. SA-loaded SLMs were then produced by a hot emulsion technique followed by high-shear homogenisation and the manufacturing parameters were optimized using the experimental design methodology in order to reach a suitable particle size for pulmonary administration. Scanning electron micrographs showed that SLMs are spherical, have a smooth surface and that SA crystallizes outside of the particles when the drug loading is higher than 20%. This was confirmed by X-ray diffraction. SA in vitro release study from SLMs showed that the release rate increased with SA loading but remained in every case lower than the dissolution rate of pure SA.
Collapse
Affiliation(s)
- Séverine Jaspart
- Laboratory of Pharmaceutical Technology, Department of Pharmacy, University of Liège, Belgium.
| | | | | | | | | | | |
Collapse
|
11
|
Cook RO, Pannu RK, Kellaway IW. Novel sustained release microspheres for pulmonary drug delivery. J Control Release 2005; 104:79-90. [PMID: 15866336 DOI: 10.1016/j.jconrel.2005.01.003] [Citation(s) in RCA: 113] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2004] [Revised: 01/11/2005] [Accepted: 01/18/2005] [Indexed: 12/01/2022]
Abstract
A novel process for generating sustained release (SR) particles for pulmonary drug delivery is described. High purity nanoparticles of a hydrophilic, ionised drug are entrapped within hydrophobic microspheres using a spray-drying approach. Sustained release of the model drug, terbutaline sulphate (TS), from the microspheres was found to be proportional to drug loading and phospholipid content. Microspheres with a 33% drug loading exhibited sustained release of 32.7% over 180 min in phosphate buffer. Release was not significantly different in simulated lung fluids. No significant burst release was observed which suggested that nanoparticles were coated effectively during spray-drying. The absence of nanoparticles at the microsphere surface was confirmed with confocal microscopy. The sustained release microspheres were formulated as a carrier-free dry powder for inhalation, and exhibited a favourable Fine Particle Fraction (FPF) of 46.5+/-1.8% and Mass Median Aerodynamic Diameter (MMAD) of 3.93+/-0.12 microm.
Collapse
Affiliation(s)
- Robert O Cook
- Department of Pharmaceutics, University of London School of Pharmacy, 29/39 Brunswick Square, London, WC1N 1AX, UK.
| | | | | |
Collapse
|
12
|
Abstract
Several particle engineering technologies have recently emerged, which have enabled inhaled microspheres to seek to manipulate pulmonary biopharmaceuticals, and to improve therapeutic efficacy for both local and systemic treatments. These microspheres may be designed to sustain drug release, to prolong lung retention, to achieve drug targeting and/or to enhance drug absorption and thereby, to seek the potentials of reducing dosing frequency and/or drug dose, while maintaining therapeutic efficacy and/or reducing adverse effects. While product development is still in process, in many cases, considerable therapeutic benefits and/or new therapeutic opportunities can be envisaged. 'Proof-of-concept' results are now available for various drug classes including beta(2)-adrenoceptor agonists, corticosteroids, antimycobacterial antibacterials, estradiol and therapeutic macromolecules such as insulin. Nevertheless, their development success must overcome several critical and unique challenges including toxicological evaluations of microsphere materials, and, clearly, successful products should meet the needs of the patient and the market place. Unfortunately, such issues have not always been addressed or examined adequately in the current studies, and thus we may anticipate paradigm shifts in the research of several groups seeking to develop products with improved therapeutic profiles. Nevertheless, it seems likely that improved inhalation products, with greater therapeutic efficacy and reduced adverse effects, will result from next-generation respirable microspheres. These may be expected to contain drugs intended for both local and systemic activity.
Collapse
Affiliation(s)
- Masahiro Sakagami
- Department of Pharmaceutics, School of Pharmacy, Aerosol Research Group, Virginia Commonwealth University, Richmond, Virginia 23298-0533, USA.
| | | |
Collapse
|
13
|
Ehrhardt C, Fiegel J, Fuchs S, Abu-Dahab R, Schaefer UF, Hanes J, Lehr CM. Drug absorption by the respiratory mucosa: cell culture models and particulate drug carriers. JOURNAL OF AEROSOL MEDICINE : THE OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY FOR AEROSOLS IN MEDICINE 2002; 15:131-9. [PMID: 12184863 DOI: 10.1089/089426802320282257] [Citation(s) in RCA: 68] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
The inhalation route is of increasing interest for both local and systemic drug delivery, including macromolecular biopharmaceuticals, such as peptides, proteins, and gene therapeutics. In addition to appropriate aerosolization for deposition in relevant areas of the respiratory tract, therapeutic molecules may require an advanced carrier system for safe and efficient delivery to their target. Two approaches to obtain novel carrier systems for pulmonary drug delivery are large porous microparticles with a low aerodynamic diameter and lectin-functionalized liposomes. Epithelial cells of alveolar or bronchial origin, obtained either from patient material or from established cell lines, can be grown on permeable filter supports, resulting in polarized monolayers with functional intercellular junctions. With such in vitro models, transport of drugs into pulmonary epithelial cells and/or across the air-blood barrier, as well as the effect and efficacy of novel drug carrier systems can be systematically studied.
Collapse
Affiliation(s)
- C Ehrhardt
- Department of Biopharmaceutics and Pharmaceutical Technology, Saarland University, Bldg. 8.1, 66123 Saarbrücken, Germany
| | | | | | | | | | | | | |
Collapse
|
14
|
Cho SW, Song SH, Choi YW. Effects of solvent selection and fabrication method on the characteristics of biodegradable poly(lactide-co-glycolide) microspheres containing ovalbumin. Arch Pharm Res 2000; 23:385-90. [PMID: 10976588 DOI: 10.1007/bf02975452] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
To demonstrate the effect of formulation conditions on the controlled release of protein from poly(lactide-co-glycolide) (PLGA) microspheres for use as a parenteral drug carrier, ovalbumin (OVA) microspheres were prepared using the W/O/W multiple emulsion solvent evaporation and extraction method. Methylene chloride or ethyl acetate was applied as an organic phase and poly(vinyl alcohol) as a secondary emulsion stabilizer. Low loading efficiencies of less than 20% were observed and the in vitro release of OVA showed a burst effect in all batches of different microspheres, followed by a gradual release over the next 6 weeks. Formulation processes affected the size and morphology, drug content, and the controlled release of OVA from PLGA microspheres.
Collapse
Affiliation(s)
- S W Cho
- Department of Pharmaceutics, College of Pharmacy, Chung-Ang University, Seoul, Korea
| | | | | |
Collapse
|
15
|
Ben-Jebria A, Chen D, Eskew ML, Vanbever R, Langer R, Edwards DA. Large porous particles for sustained protection from carbachol-induced bronchoconstriction in guinea pigs. Pharm Res 1999; 16:555-61. [PMID: 10227712 DOI: 10.1023/a:1018879331061] [Citation(s) in RCA: 81] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
PURPOSE To determine whether a new formulated albuterol aerosol could sustain inhibition to bronchoconstriction for approximately one day in guinea pigs challenged with carbachol. METHODS Large and porous particles, comprising a combination of endogenous or FDA-approved excipients and albuterol sulfate, were prepared by spray drying using a NIRO portable spray drier. The anesthetized animals inhaled 5 mg of large porous or small nonporous particles by forced ventilation via cannulae inserted in the lumen of their exposed tracheae. At regular intervals over a period of 36 hours after drug delivery, airway resistance was determined in response to carbachol challenge dose. RESULTS Whereas inhalation of small nonporous albuterol particles protected from the carbachol-induced bronchoconstriction for up to 5 hours, inhalation of large porous albuterol particles produced a significant inhibition of carbachol-induced bronchoconstriction for at least 16 hours. CONCLUSIONS The absence of substantial side effects, verified over a period of 24 hours by evaluating cardio-respiratory parameters as well as pulmonary inflammation, supports the utility of large porous albuterol particles for sustained therapies in asthma and other types of lung disease.
Collapse
Affiliation(s)
- A Ben-Jebria
- Department of Chemical Engineering, The Pennsylvania State University, University Park 16802, USA.
| | | | | | | | | | | |
Collapse
|
16
|
Uchida T, Shiosaki K, Nakada Y, Fukada K, Eda Y, Tokiyoshi S, Nagareya N, Matsuyama K. Microencapsulation of hepatitis B core antigen for vaccine preparation. Pharm Res 1998; 15:1708-13. [PMID: 9833992 DOI: 10.1023/a:1011904627929] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
PURPOSE To prepare poly(lactide-co-glycolide)(PLGA) microspheres containing recombinant hepatitis B core antigen (HBcAg; Mw = 3,600,000) by a w/o/w emulsion/solvent evaporation method and evaluate the possibility of this system as a potent long-acting carrier for hepatitis B core antigen in mice. METHODS Various additives had been incorporated in the internal aqueous phase during the process of microencapsulating HBcAg, HBcAg antigenicity in the medium extracted from the prepared microspheres were measured by ELISA. Shape confirmation of the HBcAg antigen was performed by a sucrose gradient velocity centrifugal technique. For in vivo study, prepared microspheres were administered subcutaneously to Balb/C mice, and the serum IgG level was determined by ELISA. RESULTS The inactivation of HBcAg by methylene chloride was dramatically reduced by the addition of gelatin (4-8% (w/v)) to the internal aqueous phase during the preparation. Further improvement of the loading efficiency to almost 61% resulted with cooling (4 degrees C). The prepared microspheres (4.27 microm+/-1.23 microm) containing 0.15% HBcAg displayed burst release (50-60% within 2 days). In subcutaneous inoculation, the adjuvant effect of PLGA microspheres was almost the same as that of the complete Freund's adjuvant. Whereas oral inoculation using the microspheres was not effective. CONCLUSIONS The pH of the added gelatin seemed to be the key to the stabilization of HBcAg from various stability tests and CD spectrum study. Finally, the possibility of using this system as a potent long-acting hepatitis B vaccine was demonstrated.
Collapse
Affiliation(s)
- T Uchida
- School of Pharmaceutical Sciences, Mukogawa Women's University, Nishinomiya City, Japan
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Evora C, Soriano I, Rogers RA, Shakesheff KN, Hanes J, Langer R. Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: the effect of 1,2-dipalmitoylphosphatidylcholine. J Control Release 1998; 51:143-52. [PMID: 9685911 DOI: 10.1016/s0168-3659(97)00149-1] [Citation(s) in RCA: 119] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
This study examines the potential of 1,2-dipalmitoylphosphatidylcholine (DPPC), a major component of lung surfactant, to reduce the phagocytosis of microspheres by altering the cellular interactions occurring in the alveoli. These microspheres could be designed to act as a controlled delivery system for small molecules, peptides or proteins for pulmonary administration. Microspheres were prepared using poly (lactic-co-glycolic acid) (PLGA, 50/50 and encapsulated peroxidase as a model protein. DPPC was included in some formulations. The interaction of PLGA and DPPC-PLGA microspheres with phagocytic cells was evaluated using lung macrophages in culture. X-ray Photoelectron Spectra (XPS) results indicate that the inclusion of DPPC in the microspheres alters the microsphere surface chemistry, with the DPPC covering a large portion of the microsphere surface. The dominance of DPPC on the microsphere surface is highly beneficial in moderating the interaction occurring between the microspheres and phagocytic cells in the lung. Fluorescent confocal microscopy indicates that only 25% of cells internalized DPPC-coated particles, whereas 70% of those cells exposed to particles without the DPPC coating internalized particles after one hour of incubation.
Collapse
Affiliation(s)
- C Evora
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge 02139, USA
| | | | | | | | | | | |
Collapse
|
18
|
PHILIP VINODA, MEHTA RAHULC, DELUCA PATRICKP, MAZUMDER MALAKK. E-SPART Analysis of Poly (D, L-lactide-co-glycolide) Microspheres Formulated for Dry Powder Aerosols. PARTICULATE SCIENCE AND TECHNOLOGY 1997. [DOI: 10.1080/02726359708906773] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
19
|
Concessio NM, Hickey AJ. Descriptors of irregular particle morphology and powder properties. Adv Drug Deliv Rev 1997; 26:29-40. [PMID: 10837530 DOI: 10.1016/s0169-409x(97)00508-5] [Citation(s) in RCA: 50] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
The description of irregular particle morphology and powder properties may offer unique insights into the performance of materials intended for use in dry powder inhalers. A number of mathematically similar approaches have been used to study these phenomena, all based on evaluating data in terms of irregular oscillations around a mean value. The specific methods described are Fourier, fractal and chaos analysis, stochastic and percolation models. Data describing the morphology of disodium cromoglycate particles, the behaviour of lactose and sodium chloride powders and dispersion of Intal((R)) (disodium cromoglycate/lactose blend) utilizing a Spinhaler((R)) is presented to demonstrate the application of these approaches to dry powder inhaler systems. It is envisaged that these techniques may be used to characterize powders with a view to guiding formulation and that ultimately this may lead to a greater understanding of the nature and magnitude of performance variables.
Collapse
Affiliation(s)
- NM Concessio
- School of Pharmacy, University of North Carolina, Beard Hall, CB#7360, Chapel Hill, NC 27599-7360, USA
| | | |
Collapse
|
20
|
Murakami H, Kawashima Y, Niwa T, Hino T, Takeuchi H, Kobayashi M. Influence of the degrees of hydrolyzation and polymerization of poly(vinylalcohol) on the preparation and properties of poly(dl-lactide-co-glycolide) nanoparticle. Int J Pharm 1997. [DOI: 10.1016/s0378-5173(96)04854-5] [Citation(s) in RCA: 87] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
21
|
Peptide containing microspheres from low molecular weight and hydrophilic poly(d,l-lactide-co-glycolide). J Control Release 1996. [DOI: 10.1016/0168-3659(96)01332-6] [Citation(s) in RCA: 135] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
|
22
|
Uchida T, Yagi A, Oda Y, Goto S. Microencapsulation of ovalbumin in poly(lactide-co-glycolide) by an oil-in-oil (o/o) solvent evaporation method. J Microencapsul 1996; 13:509-18. [PMID: 8864988 DOI: 10.3109/02652049609026036] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
The objective of this study was to produce biodegradable poly(lactide-co-glycolide) (PLGA; 50/50) microspheres by an oil-in-oil (o/o) solvent evaporation method to prolong the in vitro release of ovalbumin (OVA) as a model protein. The effects, on loading efficiency, microsphere yield, morphology and drug release, of two dispersing agents, aluminium tristearate and Span 80, in mineral oil were examined. PLGA 50/50 microspheres containing OVA powder (sieved through a 53 microns mesh) were prepared using an o/o solvent evaporation method. When aluminum tristearate was employed as a dispersing agent, the loading efficiency and yield of OVA had maximum values of 89 and 72% at 0.15% (w/v) aluminum tristearate, respectively. Morphology studies suggested that the obtained microspheres were spherical, and had a smooth surface. The diameters of the microspheres ranged between 100 and 200 microns. The loading efficiency, or yield, for microspheres decreased significantly above or below 0.15% (w/v) aluminum tristearate, and microspheres with irregular shapes were observed. The minimum sedimentation volume ratio (F) was obtained at a dispersity of carbon black particles in ethanol containing 0.15% (w/v) aluminum tristearate by a sedimentation study, and the cloudy supernatant suggested a deflocculated suspension. However, on the contrary, when Span 80 was added into the mineral oil as a dispersing agent, the concentration of Span 80 had little or no effect on the characteristics of the prepared microspheres. Drug loadings (60-70%) were obtained within the Span 80 concentrations employed in the present study (0.05-1.0% (w/v)). The yields were also in the same levels. The microspheres prepared in mineral oil containing Span 80 had an average diameter less than 50 microns in all cases. Sustained-release characteristics were demonstrated for PLGA microspheres prepared in mineral oil containing aluminum tristearate as a dispersing agent, even though a burst release at the initial phase was observed. This initial burst release from PLGA microspheres was reduced to some extent by micronization of the OVA powder using a planetary-type ball mill. However, PLGA microspheres prepared in mineral oil containing Span 80 as a dispersing agent, exhibited a large initial burst release. This burst release seems to be due to the smaller size of microspheres and the OVA powder adhering to the surface of PLGA microspheres (confirmed by scanning electron microscope (SEM) study).
Collapse
Affiliation(s)
- T Uchida
- Faculty of Pharmaceutical Sciences, Kyushu University, Fukuoka City, Japan
| | | | | | | |
Collapse
|
23
|
Uchida T, Yoshida K, Goto S. Preparation and characterization of polylactic acid microspheres containing water-soluble dyes using a novel w/o/w emulsion solvent evaporation method. J Microencapsul 1996; 13:219-28. [PMID: 8999126 DOI: 10.3109/02652049609052909] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Polylactic acid (PLA) microspheres containing soluble dyes as water-soluble model compounds were prepared using the water-in-oil-in-water (w/o/w) emulsion solvent evaporation method. Addition of electrolytes such as NaCl or CaCl2 into the external aqueous phase significantly improved brilliant blue (BB) entrapment efficiency compared to the case of no additives. NaCl was the most effective for obtaining high entrapment efficiency (80-90% of theoretical BB content). The average diameter of the obtained microspheres was in the region of 10-20 microns in all cases. PLA microspheres containing 5 and 10% (w/w) BB exhibited the so-called burst release. The release rate decreased with decrease in the internal aqueous droplet volume in the preparation process. In particular, with PLA microspheres containing 5% (w/w) BB, those prepared with the smallest internal droplet volume (63 microliter), the initial burst release was reduced significantly, and 50% (w/w) of the loaded BB remained in the microspheres for 7 days.
Collapse
Affiliation(s)
- T Uchida
- Faculty of Pharmaceutical Sciences, Kyushu University, Fukuoka City, Japan
| | | | | |
Collapse
|
24
|
|
25
|
Uchida T, Goto S, Foster TP. Particle size studies for subcutaneous delivery of poly(lactide-co-glycolide) microspheres containing ovalbumin as vaccine formulation. J Pharm Pharmacol 1995; 47:556-60. [PMID: 8568620 DOI: 10.1111/j.2042-7158.1995.tb06713.x] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
The primary objectives of the present study were to produce poly(lactide-co-glycolide) (PLGA) microspheres with different diameters, to characterize these microspheres which were loaded with a model antigen, ovalbumin and to evaluate the effect of microsphere particle size on the serum antibody levels following administration to mice. Four kinds of ovalbumin-loaded PLGA microspheres with different diameters (1.2, 3.5, 7.0 and 14.3 microns as mean volume diameter) were manufactured by a w/o/w emulsion/solvent evaporation method. Low loading percent (0.08%-0.25% w/w) and efficiencies (8-25% w/w) were observed. Examination using scanning electron photomicrographs showed smooth spherical particles. The in-vitro release of ovalbumin from microspheres showed an expected burst release with all batches and the extent of the burst release increased with decreasing diameters of spheres; PLGA microspheres with the smallest diameter (1.2 microns) showed an 80% burst release within one day. Approximately 10-60% of ovalbumin remained unreleased 30 days later. The single subcutaneous administrations of ovalbumin-loaded PLGA microspheres with different diameters to mice induced good antibody responses above ovalbumin saline negative controls at 3, 6, 9, and 12 weeks after inoculation. Especially, 0.16% ovalbumin-loaded PLGA microspheres having mean volume diameter of 3.5 microns exhibited the best immune responses with values greater than those obtained after inoculation with adjuvants such as complete Freund's adjuvant or alum as positive control. The strong adjuvant activity of PLGA microspheres as vaccine formulation was suggested.
Collapse
Affiliation(s)
- T Uchida
- Faculty of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan
| | | | | |
Collapse
|
26
|
Byron PR, Patton JS. Drug delivery via the respiratory tract. JOURNAL OF AEROSOL MEDICINE : THE OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY FOR AEROSOLS IN MEDICINE 1993; 7:49-75. [PMID: 10147058 DOI: 10.1089/jam.1994.7.49] [Citation(s) in RCA: 137] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Inhalation offers an enormous absorptive surface area for rapid drug absorption and substantial absorption of polypeptides. Due to slow clearance from the lower lung, even compounds with very small absorption rates can be absorbed in significant quantities over 10-12h periods. Aerosol dosimetry problems can also be minimized when lung-normal patients are considered. In the near future, optimal formulations will be combined with modified aerosol delivery devices to achieve reproducible dosing. These will be used as alternatives to parenteral delivery for drug doses of the order of milligrams or less. Research on the molecular structural dependence of lung disposition is in its infancy. Absorption kinetics for small molecules are known to depend on lipophilicity and molecular size. For macromolecules however, electronic charge and site of deposition may be additional determinants of bioavailability. Carrier-mediated absorption processes may also be important. The pulmonary absorption of a number of molecules is reviewed with special emphasis on new and promising products of biotechnology like human insulin and human growth hormone. Delivery improvements in the future should ensure, ideally, that nondenatured, monomeric pure compounds are delivered reproducibly and predominantly to the lung itself, so that these compounds may elicit reproducible systemic effects following absorption.
Collapse
Affiliation(s)
- P R Byron
- Aerosol Research Group, School of Pharmacy, Virginia Commonwealth University, Medical College of Virginia, Richmond 23298
| | | |
Collapse
|
27
|
|